MA44006A - Inhibiteur pde1 - Google Patents
Inhibiteur pde1Info
- Publication number
- MA44006A MA44006A MA044006A MA44006A MA44006A MA 44006 A MA44006 A MA 44006A MA 044006 A MA044006 A MA 044006A MA 44006 A MA44006 A MA 44006A MA 44006 A MA44006 A MA 44006A
- Authority
- MA
- Morocco
- Prior art keywords
- pde1 inhibitor
- pde1
- inhibitor
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294329P | 2016-02-12 | 2016-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44006A true MA44006A (fr) | 2021-04-14 |
Family
ID=58044210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044006A MA44006A (fr) | 2016-02-12 | 2017-02-03 | Inhibiteur pde1 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9868741B2 (fr) |
| EP (1) | EP3414249B1 (fr) |
| JP (1) | JP6533875B2 (fr) |
| CN (1) | CN108602835A (fr) |
| AR (1) | AR107456A1 (fr) |
| ES (1) | ES2879645T3 (fr) |
| MA (1) | MA44006A (fr) |
| TW (1) | TWI609870B (fr) |
| WO (1) | WO2017139186A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JOP20170164A1 (ar) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
| CN109843884B (zh) | 2016-10-18 | 2022-03-04 | H.隆德贝克有限公司 | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 |
| EP3532064B1 (fr) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
| AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| TW201920188A (zh) | 2017-08-10 | 2019-06-01 | 美商美國禮來大藥廠 | [1,2,4]三唑衍生物 |
| JP7254078B2 (ja) * | 2017-11-27 | 2023-04-07 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物 |
| US11453673B2 (en) | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
| WO2021035157A1 (fr) * | 2019-08-22 | 2021-02-25 | Intra-Cellular Therapies, Inc. | Composés organiques |
| WO2022138757A1 (fr) * | 2020-12-24 | 2022-06-30 | デンカ株式会社 | Construction d'adn, vecteur, bactérie et procédé de production de polypeptide |
| WO2025059641A1 (fr) | 2023-09-14 | 2025-03-20 | Eli Lilly And Company | Inhibiteurs de la pde1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| FR2662163A1 (fr) * | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| AU9651198A (en) * | 1997-11-11 | 1999-05-31 | Ono Pharmaceutical Co. Ltd. | Fused pyrazine compounds |
| DE19858331A1 (de) * | 1998-12-17 | 2000-06-21 | Boehringer Ingelheim Pharma | Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren |
| CA2671980C (fr) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Derive de quinoxaline |
| WO2008103357A1 (fr) | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | 1,2,4-triazoles tricycliques fongicides |
| JP5822080B2 (ja) | 2010-09-07 | 2015-11-24 | アステラス製薬株式会社 | キノキサリン化合物 |
| AU2013277294C1 (en) | 2012-06-18 | 2018-02-08 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
-
2017
- 2017-01-26 TW TW106103200A patent/TWI609870B/zh not_active IP Right Cessation
- 2017-01-26 AR ARP170100205A patent/AR107456A1/es unknown
- 2017-02-03 JP JP2018539268A patent/JP6533875B2/ja not_active Expired - Fee Related
- 2017-02-03 WO PCT/US2017/016343 patent/WO2017139186A1/fr not_active Ceased
- 2017-02-03 US US15/423,626 patent/US9868741B2/en active Active
- 2017-02-03 MA MA044006A patent/MA44006A/fr unknown
- 2017-02-03 CN CN201780010789.0A patent/CN108602835A/zh active Pending
- 2017-02-03 ES ES17705269T patent/ES2879645T3/es active Active
- 2017-02-03 EP EP17705269.3A patent/EP3414249B1/fr active Active
- 2017-12-07 US US15/834,256 patent/US10112951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170233396A1 (en) | 2017-08-17 |
| TW201736372A (zh) | 2017-10-16 |
| US10112951B2 (en) | 2018-10-30 |
| ES2879645T3 (es) | 2021-11-22 |
| US9868741B2 (en) | 2018-01-16 |
| AR107456A1 (es) | 2018-05-02 |
| US20180099973A1 (en) | 2018-04-12 |
| JP6533875B2 (ja) | 2019-06-19 |
| JP2019503389A (ja) | 2019-02-07 |
| EP3414249B1 (fr) | 2021-06-23 |
| CN108602835A (zh) | 2018-09-28 |
| EP3414249A1 (fr) | 2018-12-19 |
| TWI609870B (zh) | 2018-01-01 |
| WO2017139186A1 (fr) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| MA44006A (fr) | Inhibiteur pde1 | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3405050T3 (da) | Børnesikret snusbeholder | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3681884T3 (da) | Rad51-inhibitorer | |
| EP3313828A4 (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3436823T3 (da) | Antigen-array | |
| ME03414B (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| DK3335532T3 (da) | Tandharve | |
| DK3402792T3 (da) | Quinolin-2-on-derivater | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| DK3445708T3 (da) | Stigbøjle | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3452590T3 (da) | Plademagnet | |
| EP3502111A4 (fr) | Inhibiteur de pde4 | |
| EP3600301A4 (fr) | Inhibiteurs de kdm4 | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| EP3498837A4 (fr) | Procédé d'édition de génome | |
| DK3481826T3 (da) | Tyrosinkinaseinhibitorer | |
| LT3126354T (lt) | Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai | |
| DE112017000734A5 (de) | Glycolsensor | |
| DE112017006386A5 (de) | Schraubarbeitszylinder |